Developing new drugs for the treatment of lymphoma.

Developing new drugs for the treatment of lymphoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Developing new drugs for the treatment of lymphoma. Abstract Text:

Despite the great progress that has been made over the last several decades in the treatment of lymphoma, the prognosis for patients with relapsed disease, and particular sub-types of lymphoma like mantle cell and T cell lymphoma, remains quite poor. While major advances in the use of combination chemotherapy, monoclonal antibodies, peripheral blood stem cell transplants, and radioimmunotherapy, have provided new opportunities to alter the natural history of these diseases, and even improve cure rates among elected sub-populations of patients, these 'traditional' approaches have not benefited all patients, or subtypes of lymphoma. The incredibly rapid pace of understanding the molecular basis for the discrete sub-types of both non-Hodgkin's lymphoma and Hodgkin's Disease is beginning to afford exciting new opportunities to both risk stratify patients, and to identify potentially novel 'drugable' targets. These advancements in understanding the major molecular defects in lymphoma, have provided a new context in which we can rethink the use of new and old drugs, and design new ones with unique mechanisms of action. The panoply of new targets and drugs now becoming available for the treatment of lymphoma is truly daunting. A plethora of new small molecules that target bcl-2, mTOR, histone deactylases, and NF-kB have shown promising preclinical activity, and are now promising early phase activity. In many cases, the empirical observations from early clinical trials have provided invaluable clues to potentially valuable drugs like bortezomib, depsipeptide, and SAHA, These empirical observations, based on the inclusion of patients with lymphoma on these studies, have thus far proven to be as or more valuable than any other 'rational' target based approach. In addition, beyond the novel small molecules affecting unique and heretofore unrecognized biological pathways, there continues to be a robust and important effort to identify new derivatives of older generation drugs with hopefully better activity, and less toxicity. For example, new generation anthracenediones and anti-folates, and new formations of older drugs like doxorubicin, irinotecan, and vincristine afford new opportunities to favourably change the pharmacokinetic profile of these agents, and improve their overall safety profile. While it would not be possible to address each and every new such drug, we hope to touch on some of the major new themes and agents emerging for the treatment of Hodgkin's Disease and non-Hodgkin's lymphoma.

Developing new drugs for the treatment of lymphoma. Publishing Authors By Initials

For similar neoplasms: neoplasms by histologic type: lymphoma research abstracts see: neoplasms: neoplasms by histologic type: lymphoma research

PUBMED ID PMID:

MEDLINE DATE:

Developing new drugs for the treatment of lymphoma. Journal Published:

PUBLICATION TYPE: Review

Journal: European journal of haematology. Supplementum

VOLUME:

Page Numbers: 150-8

Journal Abbreviation:

ISSN: 0902-4506

DAY: 26

MONTH: Jul

YEAR: 2005

Developing new drugs for the treatment of lymphoma. Information

Number of References: 41

LANGUAGE: eng

NlmUniqueID: 8703474

Developing new drugs for the treatment of lymphoma. Keywords Mesh Terms:

KEYWORDS: Lymphoma

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Developing new drugs for the treatment of lymphoma. Information

Substance Name: Antineoplastic Agents

Registry Number: 0

Grant and Affiliation Information for Developing new drugs for the treatment of lymphoma.

AFFILIATION: Department of Medicine, Memorial Sloan Kettering Cancer Center, Lymphoma and Developmental Chemotherapy Services, Box 329, 1275 York Ave., New York, NY 10021, USA. oconnoro@mskcc.org

Country: Denmark

AGENCY: United States NCI

GRANT: UO1 CA 69913

ACRONYM: CA

MEDLINETA: Eur J Haematol Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Developing new drugs for the treatment of lymphoma Related Publications

• A dedicated translation factor controls the synthesis of the global regulator Fis.
• A local antigen-driven humoral response is present in the inflammatory myopathies.
• A method for identifying mechanisms of neurologic injury from cardiac surgery.
• Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension.
• Childhood behavior problems and peer selection and socialization: risk for adolescent alcohol use.
• Comprehensive characterization of MHC class II haplotypes in Mauritian cynomolgus macaques.
• Control of simian immunodeficiency virus SIVmac239 is not predicted by inheritance of Mamu-B*17-containing haplotypes.
• Cytomics: A multiparametric, dynamic approach to cell research.
• Detailed map of oxidative post-translational modifications of human p21ras using Fourier transform mass spectrometry.
• Educational notes, disclaimers, and recommendations appended to cervical cytologic reports.
• Executive functioning predicts social skills following prenatal alcohol exposure.
• Growth hormone regulation of sex-dependent liver gene expression.
• Heredity of endothelin secretion: human twin studies reveal the influence of polymorphism at the chromogranin A locus, a novel determinant of endothelial function.
• Hyperglycosylated HCG expression in pregnancy: cellular origin and clinical applications.
• LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells.
• Mass media and the prevention of drug problems: a psychological appraisal.
• Measurement of endocervical canal extension of the transformation zone on fresh hysterectomy specimens.
• Pediatrician characteristics associated with child abuse identification and reporting: results from a national survey of pediatricians.
• Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion.
• Population-based sample reveals gene-gender interactions in blood pressure in White Americans.
• Quantitating the relative abundance of isoaspartyl residues in deamidated proteins by electron capture dissociation.
• Quantitative determination of isotope ratios from experimental isotopic distributions.
• Removal of polyethylene glycols from protein samples using titanium dioxide.
• Renal albumin excretion: twin studies identify influences of heredity, environment, and adrenergic pathway polymorphism.
• Simian immunodeficiency virus SIVmac239 infection of major histocompatibility complex-identical cynomolgus macaques from Mauritius.
• Smoking status as a clinical indicator for alcohol misuse in US adults.
• Spook and Spookier code for stage-specific components of the ecdysone biosynthetic pathway in Diptera.
• Stimulants, neuroleptics, and children's friendship training for children with fetal alcohol spectrum disorders.
• The effect of radical trap moieties on electron capture dissociation spectra of substance P.
• Use of the filter diagonalization method in the study of space charge related frequency modulation in fourier transform ion cyclotron resonance mass spectrometry.